-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Tcr2 Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2018 to Q1 2023.
- Tcr2 Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending March 31, 2023 was -$40.4M, a 38.7% decline year-over-year.
- Tcr2 Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending March 31, 2023 was -$163M, a 51.8% decline year-over-year.
- Tcr2 Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$152M, a 52.1% decline from 2021.
- Tcr2 Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$99.8M, a 48.7% decline from 2020.
- Tcr2 Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$67.1M, a 41% decline from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)